Business
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib \nServed as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2\nSAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer (CMO). Dr. Kabbinavar will oversee the clinical development program for the Company's investigational drug onvansertib and will report directly to Chief Executive Officer, Mark Erlander, PhD.\n\n \n \n \n \n \n \n\n \nDr. Kabbinavar joins Cardiff Oncology with more than 30 years of experience that bridges both the academic and biotech/pharmaceutical sectors. He spent 25 years as an academic oncologist at the University of California, Los Angeles (UCLA), holding appointments including professor of medicine and urologic oncology. He joined the biotech industry as the principal medical director in Genentech's immuno-oncology program, where he led the clinical development of atezolizumab (TECENTRIQ®) in extensive stage small cell lung cancer and oversaw the filing of the supplemental biologics license application that led to the drug's FDA approval. Most recently, Dr. Kabbinavar was the global head of research and development at Huyabio International. Prior to joining Huyabio, he served as senior vice president (SVP) of clinical research and development at Puma Biotechnology, and CMO and SVP of clinical development at Tocagen, Inc. \n\"As both a clinical oncologist and biopharma executive, Fairooz brings deep knowledge of colorectal cancer, our lead indication for onvansertib, as well as other solid tumor cancers,\" said Mark Erlander, PhD, chief executive officer of Cardiff Oncology. \"His experience guiding the development and registration of high-impact oncology drugs adds critical and relevant expertise to the Cardiff team. The deep relationships Fairooz has with investigators and clinical trial sites worldwide, includ...